Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.
S. 1435, the Affordable Prescriptions for Patients Act.
H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act.
H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act.
H.R. 2883 Stop Stalling Access to Affordable Medications
H.R. 2891 Preserve Access to Affordable Generics and Biosimilars Act
Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform
S. 2428, the False Claims Amendments Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform 
S. 1435, the Affordable Prescriptions for Patients Act H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 19 / S. 2164, the Lower Costs, More Cures Act.
H.R. 3749, To amend title XXVII of the Public Health Services Act to expand the availability of coverage for lung cancer screenings without the imposition of cost sharing.
Issues related to Cures 2.0.
Issues related to drug pricing.
COVID-19 vaccine and therapy development.
Issues related to health equity and clinical trials
H.R. 5376 Build Back Better Act
Issues related to drug regulation & approval pathways
S.2911, Seniors Prescription Drug Relief Act
Issues related to value-based arrangements
Oncology Care Model / Oncology Care First
H.R. 1730/S. 670- Speeding Therapy Access Today Act; 
H.R. 483/S. 350 - Newborn Screening Saves Lives Act
Diverse and Equitable Participation in Clinical Trials Act Discussion Draft  
General issues related to orphan disease drugs; 
FDA modernization policy issues; 
Reauthorization of newborn screening programs;
Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients;
General issues related to diagnostics for patients with rare diseases
Cancer screening, diagnostics and treatment 
H.R 5260 Reduced Costs and Continued Cares Act
Cancer screening, diagnostics and treatment 
Prescription drug electronic labeling Issues related to Medicare Parts B and D pricing reform, H.R. 3684, S. 2327, Senate
S. 1971, the Chronic Kidney Disease Improvement in Research and Treatment Act.
Issues related to CMS rulemaking [CMS-4190-F3, CMS-2482-P2].
S. 2614, the NOVEL Act
Medicare Multi-Cancer Early Detection Screening Coverage; H.R. 1946, S. 1873
H.R. 5030, S. 2706 DIVERSE Trails Act
H.R. 3085, S. 1548 ENACT Act of 2021
H.R. 5260 - Reduced Costs and Continued Cures Act; Build Back Better Act 
General issues related to patient access to rare disease therapies, Part B and Part D drugs;
Issues related to home infusion for Part B patients;
Value-based payment arrangements; 
Efforts to improve coding, coverage, and access for rare disease therapies; 
Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; 
General issues related to telemedicine
Issues related to 340B H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act 
H.R. 6119 Further Extending Government Funding Act Issues related to the 340B drug discount program.
Discussions related to an appropriations hold on funding for a 2014 FDA rule that would move package inserts (PI) from paper to digital form-e-labeling.
FY2022 Budget Resolution (S.Con.Res.14) and Budget Reconciliation (H.R.5376) Issues related to international and corporate tax reform.
H.R. 5376 Build Back Better Act 
Issues related to the Orphan Drug Tax Credit
TRD - Trade (domestic/foreign) CPT - Copyright/Patent/Trademark HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy TAX - Taxation/Internal Revenue Code
136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office 136 - Centers For Medicare and Medicaid Services (CMS) 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 21 - Office of Science & Technology Policy (OSTP) 1 - SENATE 12 - White House Office
ASTRAZENECA PHARMACEUTICALS LP
1800 CONCORD PIKE, P.O. BOX 15437, WILMINGTON, DE, 19850, US
SUSIE AHN AARON W HUNTER HELEN DWIGHT ELIZABETH BROOKS KATIE JONES HELEN DWIGHT AARON W HUNTER ELIZABETH BROOKS SUSIE AHN THADDEUS FLOOD KATIE JONES CAROLINE QUAT HELEN DWIGHT AARON W HUNTER ELIZABETH BROOKS SUSIE AHN THADDEUS FLOOD KATIE JONES CAROLINE QUAT HELEN DWIGHT SUSIE AHN THADDEUS FLOOD AARON W HUNTER ELIZABETH BROOKS CAROLINE QUAT KATIE JONES HELEN DWIGHT AARON W HUNTER ELIZABETH BROOKS SUSIE AHN THADDEUS FLOOD KATIE JONES CAROLINE QUAT HELEN DWIGHT SUSIE AHN AARON W HUNTER ELIZABETH BROOKS CAROLINE QUAT SUSIE AHN HELEN DWIGHT ELIZABETH BROOKS KATIE JONES